腹腔镜与开腹全胃切除术治疗临床I期胃癌的并发症与死亡率:CLASS02多中心随机临床试验
CLASS02研究为前瞻性、多中心、开放标签、非劣效性随机试验,纳入227例临床I期胃癌患者,比较腹腔镜全胃切除术(LTG)与开腹全胃切除术(OTG)联合淋巴结清扫的安全性。主要终点为术后30天内并发症与死亡率,非劣效界值10%。分析214例,两组总体并发症与死亡率差异无统计学意义(率差-1.1%,95%CI -11.8%至9.6%),LTG安全性不劣于OTG。
要点
- LTG联合淋巴结清扫治疗临床I期胃癌的30天并发症与死亡率非劣于OTG。
- 两组总体并发症与死亡率率差-1.1%(95%CI -11.8%至9.6%),未超非劣效界值。
- 术后并发症严重程度分布及术中并发症率两组相似。
核心结论
- 由经验丰富外科医师实施LTG联合淋巴结清扫治疗临床I期胃癌的安全性不劣于OTG。
研究设计与样本
- CLASS02为前瞻性、多中心、开放标签、非劣效性随机临床试验,2017年1月至2018年9月入组227例临床I期胃癌患者,随机分为LTG组113例与OTG组114例。
主要发现
- 214例纳入分析(LTG组105例,OTG组109例),总体并发症与死亡率率差-1.1%(95%CI -11.8%至9.6%)。
- 术中并发症LTG组3例(2.9%)、OTG组4例(3.7%),率差-0.8%(95%CI -6.5%至4.9%)。
- 术后总体并发症率LTG组18.1%、OTG组17.4%,率差0.7%(95%CI -9.6%至11.0%)。
- LTG组1例死于脾动脉出血继发腹腔内出血,两组死亡率率差1.0%(95%CI -2.5%至5.2%),并发症严重程度分布相似。
关键数值与推荐
- 主要终点为非劣效性检验,非劣效界值为10%。
临床怎么用
- 对于临床I期胃癌,经验丰富的外科医师可考虑采用LTG联合淋巴结清扫,其安全性不劣于OTG。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The safety of laparoscopic total gastrectomy (LTG) for the treatment of gastric cancer remains uncertain given the lack of high-level clinical evidence. OBJECTIVE: To compare the safety of LTG for clinical stage I gastric cancer with that of conventional open total gastrectomy (OTG). DESIGN, SETTING, AND PARTICIPANTS: The Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group CLASS02 study was a prospective, multicenter, open-label, noninferiority, randomized clinical trial that compared the safety of LTG vs OTG with lymphadenectomy for patients with clinical stage I gastric cancer. From January 2017 to September 2018, a total of 227 patients were enrolled. Final follow-up was in October 2018. INTERVENTIONS: Eligible patients were randomized to LTG (n = 113) or OTG (n = 114) by an interactive web response system. MAIN OUTCOMES AND MEASURES: The primary outcome was the morbidity and mortality within 30 days following surgeries between LTG and OTG with a noninferiority margin of 10%. The secondary outcomes were recovery courses and postoperative hospital stays. RESULTS: A total of 214 patients were analyzed for morbidity and mortality (105 patients in the LTG group and 109 patients in the OTG group). The mean (SD) age was 59.8 (9.4) years in the LTG group and 59.4 (9.2) years in the OTG group, and most were male (LTG group, 75 of 105 [71.4%]; OTG group, 80 of 109 [73.4%]). The overall morbidity and mortality rates were not significantly different between the groups (rate difference, -1.1%; 95% CI, -11.8% to 9.6%). Intraoperative complications occurred in 3 patients (2.9%) in the LTG group and 4 patients (3.7%) in the OTG group (rate difference, -0.8%; 95% CI, -6.5% to 4.9%). In addition, there was no significant difference in the overall postoperative complication rate of 18.1% in the LTG group and 17.4% in the OTG group (rate difference, 0.7%; 95% CI, -9.6% to 11.0%). One patient in the LTG group died from intra-abdominal bleeding secondary to splenic artery hemorrhage. However, there was no significant difference in mortality between the LTG group and the OTG group (rate difference, 1.0%; 95% CI, -2.5% to 5.2%), and the distribution of complication severity was similar between the 2 groups. CONCLUSIONS AND RELEVANCE: The results of the CLASS02 trial showed that the safety of LTG with lymphadenectomy by experienced surgeons for clinical stage I gastric cancer was comparable to that of OTG. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03007550.
引用
- Liu F, Huang C, Xu Z, et al. Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 32815991. doi:10.1001/jamaoncol.2020.3152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。